Arsenic Trioxide
| Evidence Level: L5 | Predicted Indications: 52 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Arsenic Trioxide |
| DrugBank ID | DB01169 |
| Brand Names (EU) | Arsenic trioxide Accord, Arsenic trioxide medac |
| Evidence Level | L5 |
| Predicted Indications | 52 |
| Top Prediction Score | 99.93% |
Approved Indication (EMA)
Arsenic trioxide medac is indicated for induction of remission, and consolidation in adult patients with: Newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ? 10 x 10³/?l) in combination with all-trans-retinoic acid (ATRA) Relapsed/refractory APL (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-recep
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | unclassified myelodysplastic syndrome | 99.93% | DL |
| 2 | refractory cytopenia of childhood | 99.93% | DL |
| 3 | severe congenital hypochromic anemia with ringed sideroblasts | 99.93% | DL |
| 4 | aregenerative anemia | 99.92% | DL |
| 5 | partial deletion of the long arm of chromosome 5 | 99.92% | DL |
| 6 | myelodysplastic syndrome | 99.91% | DL |
| 7 | Ewing sarcoma | 99.89% | DL |
| 8 | dermatofibrosarcoma protuberans | 99.77% | DL |
| 9 | liposarcoma | 99.75% | DL |
| 10 | ovarian myxoid liposarcoma | 99.70% | DL |
| 11 | uterine corpus sarcoma | 99.44% | DL |
| 12 | acute myeloid leukemia with t(8;21)(q22;q22) translocation | 99.25% | DL |
| 13 | osteoarthritis | 99.21% | DL |
| 14 | acute myeloid leukemia with CEBPA somatic mutations | 99.17% | DL |
| 15 | acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) | 99.14% | DL |
| 16 | botryoid-type embryonal rhabdomyosarcoma of the vagina | 99.04% | DL |
| 17 | parameningeal embryonal rhabdomyosarcoma | 99.01% | DL |
| 18 | osteoarthritis susceptibility | 99.01% | DL |
| 19 | extrahepatic bile duct rhabdomyosarcoma | 98.98% | DL |
| 20 | embryonal extrahepatic bile duct rhabdomyosarcoma | 98.95% | DL |
Showing top 20 of 52 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.